Clinical Trials on Wet AMD in United Kingdom

Total 160891 results

Oraya Therapeutics, Inc.

Withdrawn

Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)

Macular Degeneration | Age-related Macular Degeneration | AMD | Wet AMD | Wet Age-related Macular Degeneration

United Kingdom, Italy
Moorfields Eye Hospital NHS Foundation Trust

Completed

Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography (DANA)

Neovascular Age-related Macular Degeneration

United Kingdom
Retina Institute of Hawaii

Completed

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Wet AMD

United States
King's College Hospital NHS Trust
King's College London; Fight for Sight (Funder)

Recruiting

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). (TIGER)

Eye Diseases | Macular Degeneration, Wet | Sub-Macular Hemorrhage

United Kingdom
Oraya Therapeutics, Inc.

Completed

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD (INTREPID)

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Diseases | AMD | Wet AMD | Wet Age-Related Macular Degeneration

United Kingdom, Czech Republic, Austria, Germany, Italy
Royal Marsden NHS Foundation Trust
City, University of London

Unknown

Radiation Exposure Awareness From Patients Undergoing Nuclear Medicine Diagnostic Scans (REA)

FDG PET/CT | Skeletal Scintigraphy

United Kingdom
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Wet Macular Degeneration

United Kingdom, United States, Germany
Caregen Co. Ltd.
CBCC Global Research

Not yet recruiting

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Age-related Wet Macular Degeneration

United States
Bayer
Regeneron Pharmaceuticals

Terminated

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment (XPAND)

Neovascular (Wet) Age-related Macular Degeneration

Canada, United Kingdom
Kapil Kapoor

Completed

Ziv-aflibercept Efficacy in Better Regulating AMD (ZEBRA)

Wet Macular Degeneration | Wet Age-related Macular Degeneration

United States
Oraya Therapeutics, Inc.

Unknown

An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (ENDEAVOUR)

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Diseases | Wet Macular Degeneration

United Kingdom
Guy's and St Thomas' NHS Foundation Trust
Macusoft

Not yet recruiting

Artificial Intelligence Diagnostic Aid (AID)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Macular Degeneration

United Kingdom
University of Iowa

Recruiting

MMP-9 Inhibition for Recalcitrant Wet AMD

Wet Age-related Macular Degeneration | Exudative Macular Degeneration

United States
Bayer

Completed

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease (XTEND)

Wet Age-related Macular Degeneration

Canada, Spain, Sweden, Belgium, Argentina, Italy, Korea, Republic of, United Kingdom, China, Denmark, France, Norway, Colombia, Australia, Ireland, Switzerland, Thailand
Novartis

Completed

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

Wet Age-Related Macular Degeneration

United Kingdom, Switzerland
King's College Hospital NHS Trust

Completed

Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD (TAPAS)

Exudative Macular Degeneration | Retinal Hemorrhage

United Kingdom
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Exudative Macular Degeneration | Neovascular Age-elated Macular Degeneration (Wet AMD)

United States
PanOptica, Inc.

Completed

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

Neovascular Age-related Macular Degeneration

United States, Czechia, United Kingdom, Hungary, Latvia
Novartis Pharmaceuticals

Terminated

A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics

Wet Age-related Macular Degeneration

United Kingdom
Novartis Pharmaceuticals

Terminated

Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice (BESRA)

Neovascular Age-related Macular Degeneration

United Kingdom
AbbVie

Completed

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Wet Macular Degeneration | Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
Sam Chun Dang Pharm. Co. Ltd.

Completed

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
AbbVie

Recruiting

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

CNV | AMD | nAMD | Wet AMD | Wet Age-related Macular Degeneration | wAMD

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD (SAFARI)

Neovascular Age-related Macular Degeneration

Germany, United Kingdom
West Coast Retina Medical Group, Inc.
Genentech, Inc.

Unknown

Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy

Wet AMD

United States
AbbVie
AbbVie

Enrolling by invitation

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Gene Therapy | AMD | nAMD | Wet AMD | Neovascular Age-Related Macular Degeneration (nAMD) | wAMD

United States
Johns Hopkins University
Olix Pharmaceuticals, Inc.

Terminated

Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration

Wet Macular Degeneration

United States
University of California, Los Angeles
Regeneron Pharmaceuticals

Completed

The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy (IAI-OCTA)

Wet Macular Degeneration

United States
King's College Hospital NHS Trust
King's College London

Active, not recruiting

Stereotactic Radiotherapy for Wet AMD (STAR) (STAR)

Neovascular (Wet) Age-related Macular Degeneration (AMD)

United Kingdom
University of California, San Diego
Regeneron Pharmaceuticals

Completed

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection (EAGLE)

Macular Degeneration | Wet Macular Degeneration

United States
University of Edinburgh
British Heart Foundation

Recruiting

The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke (TORPIS)

Stroke | Thrombosis | PET

United Kingdom
Rishi Singh
Regeneron Pharmaceuticals

Completed

Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept

Exudative Macular Degeneration

United States
Oregon Health and Science University

Recruiting

OCT Angiography in Wet AMD

Neovascular (Wet) Age-related Macular Degeneration (AMD)

United States
Janssen Research & Development, LLC

Completed

AAVCAGsCD59 for the Treatment of Wet AMD

Wet Age-related Macular Degeneration

United States
Tyrogenex

Completed

Pilot Study of X-82 in Patients With Wet AMD

Exudative Macular Degeneration

United States
University of California, San Francisco

Terminated

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

ALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditions

United States
Duke University
Bausch & Lomb Incorporated

Completed

Photodynamic Therapy for PDA in NV AMD

Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
Ipsen

Completed

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting (PREF-NET)

Neuroendocrine Tumours (NET)

United Kingdom
University of Edinburgh
British Heart Foundation

Completed

Validation of PET-MRI for Cardiovascular Disease

Coronary Artery Disease | MRI | Cardiovascular Disease | Magnetic Resonance Imaging | Positron-Emission Tomography | PET Scan

United Kingdom
Northern California Retina Vitreous Associates
Genentech, Inc.

Completed

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept. (RESCUE)

Recalcitrant Wet Age-related Macular Degeneration

United States
Wills Eye
Mid Atlantic Retina

Completed

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration (DAWN)

Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Neovascular (Wet) Age-related Macular Degeneration

United States
AiViva BioPharma, Inc.

Completed

Effect of Intravitreally Administered AIV007 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

United States
Oregon Health and Science University

Completed

Neovascular Age-related Macular Degeneration (NVAMD)

Neovascular Age-related Macular Degeneration

United States
Duke University
Bausch & Lomb Incorporated

Withdrawn

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

Neovascular Age-related Macular Degeneration

United States
Exegenesis Bio

Recruiting

A Study of EXG102-031 in Patients With wAMD (Everest)

Neovascular (Wet) Age-related Macular Degeneration (nAMD)

United States
AbbVie
AbbVie

Enrolling by invitation

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)

Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
EyePoint Pharmaceuticals, Inc.

Completed

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

Wet Age-related Macular Degeneration

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Wet Macular Degeneration

United Kingdom, Germany, Japan, Netherlands, United States, Canada, Hungary, Italy, Mexico, Poland, Spain, Israel, Russian Federation, Switzerland, Turkey
Regeneron Pharmaceuticals

Completed

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Neovascular Wet Age-related Macular Degeneration (AMD)

United States

Clinical Trials on Wet AMD in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations